Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 13/20 | 0.62 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | FER | P16591 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048329 | 0.91 | ZAP70 (0.75) | ZAP70BRD4ATAD2IGF1RCYP3A4 | |
| SCHEMBL1048611 | 0.91 | ZAP70 (0.67) | ZAP70TGFBR1FER | |
| SCHEMBL1049379 | 0.90 | ZAP70 (0.59) | ZAP70TLR9IGF1RCYP3A4 | |
| SCHEMBL6525135 | 0.88 | ZAP70 (0.74) | ZAP70BRD4ATAD2FER | |
| SCHEMBL1049107 | 0.87 | ZAP70 (0.63) | ZAP70FER | |
| SCHEMBL1159759 | 0.86 | ZAP70 (0.64) | ZAP70BRD4ATAD2 | |
| SCHEMBL1158486 | 0.85 | ZAP70 (0.61) | ZAP70BRD4ATAD2 | |
| SCHEMBL6522850 | 0.85 | ZAP70 (0.72) | ZAP70 | |
| SCHEMBL1048447 | 0.85 | ZAP70 (0.68) | ZAP70TLR9BRD4ATAD2 | |
| SCHEMBL1048278 | 0.85 | ZAP70 (0.56) | ZAP70BRD4ATAD2FERALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885TGFBR1 2576/4885TLR9 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.